Sean Bohen, Olema president & CEO

Ole­ma gives small up­date to breast can­cer drug at cen­ter of lay­offs, 2021 da­ta leak

Ole­ma Phar­ma­ceu­ti­cals is out with more da­ta on its in­ves­ti­ga­tion­al breast can­cer drug, for which it shed 25% of its work­force two months ago to keep fund­ing its re­search.

The San Fran­cis­co-based biotech said its drug, which was at the cen­ter of a “fal­si­fied” da­ta leak in No­vem­ber 2021, was “well-tol­er­at­ed” and had no dose-lim­it­ing tox­i­c­i­ties when com­bined with Pfiz­er’s Ibrance. Ole­ma is test­ing OP-1250 in pa­tients with ER+/HER2- metasta­t­ic breast can­cer, and the safe­ty and tol­er­a­bil­i­ty up­date comes from a look at 29 pa­tients.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Vice President

Alexandria Real Estate Equities

San Francisco, CA, USA